

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Screening and surveillance of esophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct acting antiviral agents

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1844821> since 2022-03-19T11:28:20Z

Published version:

DOI:10.1111/liv.15210

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



**SCREENING AND SURVEILLANCE OF ESOPHAGEAL VARICES
IN PATIENTS WITH HCV LIVER CIRRHOSIS SUCCESSFULLY
TREATED BY DIRECT ACTING ANTIVIRAL AGENTS**

Journal:	<i>Liver International</i>
Manuscript ID	LIVint-21-01681.R2
Wiley - Manuscript type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Ciancio, Alessia; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Ribaldone, Davide; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Salamone, Rossella; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Bruno, Mauro; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Caronna, Stefania; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Debernardi-venon, Wilma; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Giordanino, Chiara; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Mondardini, Alessandra; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Musso, Alessandro; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Pennazio, Marco; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Rolle, Emanuela; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Sacco, Marco; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit; Sprujevnik, Tatiana; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit De Angelis, Claudio; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Saracco, Giorgio; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit
Keywords:	HCV, Esophagel varices, Post-SVR surveillance, Direct acting antiviral agents, Portal hypertension

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9

**SCREENING AND SURVEILLANCE OF ESOPHAGEAL VARICES IN PATIENTS
WITH HCV-POSITIVE LIVER CIRRHOSIS SUCCESSFULLY TREATED BY
DIRECT ACTING ANTIVIRAL AGENTS**

10 Running title: Impact of SVR on incidence of esophageal varices in HCV-positive cirrhotics
11 treated by DAAs
12
13
14
15
16

17 Alessia Ciancio, Davide Giuseppe Ribaldone, Rossella Salamone, Mauro Bruno, Stefania
18 Caronna, Wilma Debernardi Venon, Chiara Giordanino, Alessandra Mondardini, Alessandro
19 Musso, Marco Pennazio, Emanuela Rolle, Marco Sacco, Tatiana Sprujevnik, Claudio De
20 Angelis, Giorgio Maria Saracco.
21
22
23
24
25
26
27
28
29

30 Gastro-hepatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
31
32
33
34
35

36 Corresponding author :

37
38 Giorgio Maria Saracco, MD

39 Gastro-hepatology Unit

40 Molinette Hospital, University of Turin

41 Corso Bramante 88

42 10126 Torino, Italy

43 tel.: 39-011-6336397

44 e-mail: giorgiomaria.saracco@unito.it

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ORCID: <http://orcid.org/0000-0001-5310-4143>

Word count (only text): 4213 words.

1
2 **Tables number:** 5
3

4
5 **Figures number:** 3
6
7

8 **Abbreviation list:** HCV, hepatitis C virus; LRE, liver-related events; DAAs, direct-acting
9 antiviral agents; HCC, hepatocellular carcinoma; SVR, sustained virologic response; TE,
10 transient elastography; APRI, aspartate aminotransferase to platelet ratio; OLT, orthotopic liver
11 transplantation; HIV, Human Immunodeficiency Virus; EASL, European Association for the
12 Study of the Liver; BMI, body mass index; WC, waist circumference; DM, type 2 diabetes
13 mellitus; ALT, alanine aminotransferase; APH, alkaline phosphatase; GGT, gamma
14 glutamyltranspeptidase; US, abdominal ultrasound; MELD, model for end-stage liver diseases;
15 IQR, Inter Quartile Range; CI, confidence interval; OR, odds ratio; HR, hazard ratio; EV,
16 esophageal varices; CSPH, Clinically Significant Portal Hypertension; VNT, Varices Needing
17 Treatment
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Data availability statement:** The data that support the findings of this study are available from
36 the corresponding author upon reasonable request.
37
38
39

40 **Author Contributions:** conceptualization, G.M.S.; methodology, D.G.R.; software, M.S,
41 R.S.; validation, D.G.R. and M.S.; formal analysis, D.G.R.; investigation, R.S., S.C., D.G.R.,
42 M.S., M.B., W.D.V., C.G., A.M., M.P.E.R., T.S., C.D.A.; data curation, D.G.R., A.C., M.S.,
43 and G.M.S.; writing—original draft preparation, G.M.S.; writing—review and editing, D.G.R.
44 and M.S.; visualization, A.C., M.S.; supervision, G.M.S.; project administration, G.M.S.
45
46

47 **Permission to reproduce material from other sources:** obtained
48

49 **Potential competing interests:** all authors declare no potential conflicts of interest.
50
51
52

53 **Financial support:** the project has been partially supported by a Gilead Sciences Medical
54 Grant
55

56 **Ethics approval:** obtained
57
58

59 **Patient consent:** obtained
60

ABSTRACT

Background and aims: limited evidence is available to guide hepatologists regarding endoscopic surveillance of esophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted a long-term prospective study on 427 HCV-positive cirrhotic patients successfully treated by Direct Antiviral Agents (DAAs).

Methods: patients were divided into 2 groups according to their baseline Baveno VI status: Group 1 (92, 21.5%, favorable Baveno VI status) and Group 2 (335, 78.5%, unfavorable Baveno VI status). Each patient underwent baseline endoscopy and was endoscopically monitored for a median follow-up of 65.2 months according to Baveno VI recommendations.

Results: 4.3% of group 1 patients showed baseline EV compared with 30.1% of group 2 patients ($p < 0.0001$). No patients belonging to group 1 without baseline EV developed EV at follow-up endoscopy compared with 6.5% in group 2 patients ($p = 0.02$); 69/107 (64.5%) patients with baseline EV showed small varices. During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 ($p = 0.001$). Improvement in Baveno VI status was observed in 118/335 (35.2%, $p < 0.0001$) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up.

Conclusions: HCV-positive cirrhotic patients cured by DAAs showing baseline favorable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients having unfavorable Baveno VI status without baseline EV who improve their status may suspend further endoscopic surveillance.

Lay Summary

- Noninvasive criteria suggested by the Baveno VI and the Baveno VI expanded guidelines avoid screening endoscopies in a significant subset of cirrhotic patients but their application on long-term variceal surveillance in patients achieving sustained virologic response (SVR) by direct acting antiviral agents (DAA) is largely unknown.
- Whether further endoscopic surveillance is required in cirrhotics obtaining SVR with no esophageal varices (EV) on prior screening examination and which is the optimal endoscopic timing in patients with pre-therapy EV is still debated.
- In this study, we showed that patients having persisting favorable Baveno VI status may not undergo endoscopic surveillance while patients with unfavorable Baveno VI status and no baseline EV who improve their status may suspend further endoscopic surveillance.
- Patients with pre-therapy unfavorable Baveno VI status and small VE should maintain follow-up endoscopy at 2-year interval.

INTRODUCTION

Hepatitis C Virus (HCV) – positive cirrhotic patients achieving a sustained virologic response (SVR) by Direct Acting Antiviral Agents (DAAs) show a progressive decrease in portal pressure during follow-up reducing the risk of variceal bleeding (1). However, clinically significant portal hypertension (CSPH) may persist in a significant proportion of them (2-6). This observation has an important clinical impact by influencing our policy of screening and surveillance of esophageal varices (EV) in cured patients. Current guidelines (7-9) recommend the use of noninvasive techniques such as transient elastography (TE) and platelet count to reduce endoscopic screening: patients showing a liver stiffness measurement (LSM) <20 kPa and platelet count >150.000/mm³ can safely avoid endoscopy having a very low risk (<5%) of varices needing treatment (VNT) (10,11). According to the Baveno VI Consensus Workshop, these patients – defined as Baveno VI status favorable - can be safely followed up by yearly repetition of TE and platelet count (7). However, data supporting this recommendation are still scarce (12-14).

What it is still matter of debate is the optimal timing for surveillance endoscopy in cured patients showing unfavorable pre-therapy Baveno VI status. According to the international guidelines (7,9), in compensated patients without co-morbidities and no baseline EV or small varices prior to therapy, endoscopy should be repeated at three and two year intervals respectively. However, strength of recommendation and level of evidence are very low. A recent clinical practice update-expert review (15) by the American Gastroenterological Association (AGA) suggests follow-up endoscopy after 2-3 years in patients with no EV on prior screening examination and no further surveillance if EV are not found; patients with small EV at baseline should undergo follow-up endoscopy after 2-3 years and no further surveillance if EV unchanged or smaller.

1
2 In order to individuate the optimal type, frequency and length of EV surveillance in relation to
3
4 the clinical status of the patients, we conducted a long-term prospective study on HCV-positive
5
6 patients with compensated cirrhosis successfully treated by DAAs aiming at monitoring the
7
8 course of EV according to the Baveno VI criteria (7) as well as the impact on portal
9
10 hypertension (PH) exerted by changes of Baveno VI status.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

PATIENTS AND METHODS

This prospective cohort study included all consecutive patients with Child A-B HCV cirrhosis treated by DAAs according to the European Association for the Study of the Liver (EASL) guidelines (16) in the Gastrohepatologic Clinic of Molinette Hospital, Turin, Italy from January 1, 2015 to December 31, 2016. Inclusion criteria were as follows: > 18 years; positive HCV-RNA by polymerase chain reaction (PCR); liver cirrhosis assessed by TE and aspartate aminotransferase (AST) to platelet ratio (APRI) score. Exclusion criteria were: lack of written informed consent, TE not feasible or unreliable measurement, patients on waiting list for orthotopic liver transplant (OLT), post-OLT patients, past or current history of hepatocellular carcinoma (HCC), past or current episodes of ascites and/or encephalopathy, prophylactic banding of EV, previous episodes of variceal bleeding treated by endoscopic banding, concomitant liver diseases such as haemochromatosis, Wilson's disease, drug-related liver disease, autoimmune hepatitis, HBsAg carriership, Human immunodeficiency Virus (HIV) infection, primary biliary cholangitis, alpha-1-antitrypsin deficiency. Out of 596 consecutive patients considered for treatment with DAAs, 478 (80.2%) fulfilled the above mentioned criteria and agreed to participate; 15 out of 478 recruited patients (3.1%) did not achieve SVR and were excluded from the study. Out of 463 sustained responders, 36 (7.8%) were lost to follow up. Therefore, the final analysis was performed in 427 cirrhotic patients with SVR. Patients' flow is reported in Figure 1.

At baseline, a complete medical history and physical examination was undertaken and the following data were obtained from each patient: age, gender, ethnicity, smoking habits, alcohol intake, body mass index (BMI), waist circumference (WC), duration of HCV infection, relevant co-morbidities. The following data on laboratory parameters were also recorded to define baseline characteristics: complete blood count, routine liver biochemistry (alanine aminotransferase [ALT] and AST, total bilirubin, albumin, alkaline phosphatase [APH], gamma glutamyltranspeptidase [GGT]) international normalized ratio [INR]), creatinine,

1
2 fasting plasma glucose [FPG], total cholesterol and HDL, triglycerides, HCV genotype and
3
4 viral load [AmpliPrep®/COBAS Taqman® HCV test, Roche Diagnostics, Basel, Switzerland].

5
6
7 Severity of liver fibrosis was determined within 3 months prior to inclusion into the study by
8
9 non-invasive (AST to platelet ratio [APRI] and TE) methods. Cut-offs used to diagnose
10
11 cirrhosis were > 1.5 for APRI test and ≥ 14 kPa for TE. The reliability criteria for LSM were
12
13 as follows: 10 valid measurements achieved with a success number $\geq 60\%$ and an interquartile
14
15 range-to-median ratio $\leq 30\%$. A minimum of 3 hours fasting was required. Abdominal
16
17 ultrasound (US) was performed in each patient at baseline in order to exclude HCC.

18
19
20
21 Patients were stratified according to the Child-Turcotte-Pugh classification and Model for End-
22
23 Stage Liver Disease [MELD]; LSM and platelet count was obtained in each patient within 3
24
25 months before starting treatment in order to establish the Baveno VI status (7).

31 **Follow-up**

32
33
34 When the study was approved, upper endoscopy was still mandatory in cirrhotic patients to
35
36 assess the presence and grading of esophageal/gastric varices. For this reason, all patients
37
38 underwent oesophagogastroduodenoscopy within 3 months before starting therapy; patients
39
40 with F2/F3 EV were given Non-Selective Beta Blockers (NSBB). If intolerant or not
41
42 responding to NSBB, patients underwent prophylactic banding of EV and were excluded from
43
44 the study. In order to validate the surveillance timing suggested by Baveno VI Consensus
45
46 Workshop in a population composed by HCV-positive compensated cirrhotics successfully
47
48 treated by DAAs, we recommended the following endoscopic approach: 1) surveillance
49
50 endoscopy at three year intervals in patients with no varices at baseline endoscopy 2)
51
52 surveillance endoscopy at two year intervals in patients with small varices (F1) at baseline
53
54 endoscopy. Cirrhotic patients with large varices (F2/F3) on NSBB prophylaxis were planned
55
56 to undergo yearly endoscopy. Variceal worsening (or PH progression) was defined as the
57
58
59
60

1
2 occurrence of EV in patients with no prior EV or large EV in previous carriers of small EV, the
3
4 occurrence of grade 3 EV in patients with baseline grade 2 EV, or the onset of a variceal
5
6 bleeding.
7

8
9 Control visits were planned at 6-months intervals after achieving SVR and patients were
10
11 followed until OLT, death or until the end of June 2021. Patients were also censored at the
12
13 moment of HCC occurrence. Mortality was registered as liver-related or non-liver related. At
14
15 each control visit, medical history and physical examination were performed; liver function
16
17 tests, platelet determination, HCV-RNA assessment and liver US were recorded as well as the
18
19 occurrence of liver related events [LRE] (ascites, variceal bleeding, hepatic encephalopathy,
20
21 HCC).
22
23

24
25 More than 90% of all endoscopic procedures were performed by a pool of experienced
26
27 endoscopists (A.M., W.D.V., C.G., S.C., C.D.A., M.B., E.R., M.P., A.M, T.S..) working in our
28
29 Endoscopy Unit and adopting the Beppu's classification of EV (17). All of them were blinded
30
31 to the study design. For the aims of the study, EV were defined as: 1) no EV 2) small EV
32
33 corresponding to grade 1 EV no needing treatment 3) large EV corresponding to grade 2/3
34
35 EV needing treatment.
36
37
38

39
40 In order to check for worsening/improvement of their Baveno VI status, all patients underwent
41
42 at least 1 LSM by TE during follow-up at the time of repetition of endoscopy, at variance with
43
44 the Baveno VI recommendations suggesting yearly TE; the number of LSM reached 2 (IQR: 1-
45
46 3) and the median delay between measurements were 24.8 months (IQR: 12.4-36.6). Platelet
47
48 count was obtained during the 6-month control visits planned throughout the follow-up
49
50 (number: 10 [IQR: 8-12]).
51
52

53
54 An improvement in Baveno VI status was defined as an increase in the platelet count above
55
56 150.000/mm³ and a decrease of LSM to <20 kPa in cirrhotics with a baseline unfavorable status.

57
58 A worsening of Baveno VI status was defined as the occurrence of either platelet count
59
60

1
2 $\leq 150.000/\text{mm}^3$ or LSM ≥ 20 kPa during follow-up in patients with a baseline favorable Baveno
3
4 VI status.
5

6
7 The study was performed in accordance with the principles of the 1975 Declaration of Helsinki
8
9 and approved by our local ethics committee (Comitato Etico Interaziendale Città della Salute e
10
11 della Scienza di Torino, Turin, Italy); written informed consent was obtained from all patients.
12
13

14 15 16 **Statistical analysis**

17
18 Continuous variables were reported as median (Inter Quartile Range [IQR] and 95%
19
20 confidence interval [CI]) or geometric mean according to the data distribution. Normality was
21
22 checked by the D'Agostino–Pearson test. Categorical variables were reported as number and
23
24 percentage. Comparison of continuous variables between independent groups was performed
25
26 by the Mann–Whitney test or independent samples t-test according to data distribution;
27
28 comparison between paired measurements was performed by the Wilcoxon test or paired
29
30 samples t-test according to data distribution. Regarding the dichotomous categorical variable,
31
32 a Chi-squared test or McNemar test were performed for unpaired or paired analysis,
33
34 respectively. The association between variables was assessed by Cox proportional-hazards
35
36 regression; the strength of association was reported as hazards ratio (H.R.) and 95% CI,
37
38 accordingly. The rate of favorable and unfavorable Baveno VI status patients free from varices
39
40 has been presented by using Kaplan-Meier curves and the statistical differences were tested by
41
42 the Mantel-Cox method. Patients not developing EV were censored at last visit or at the
43
44 moment of OLT, HCC occurrence or at the date of death.
45
46

47
48 All statistical analyses were performed using MedCalc® v.18.9.1 (MedCalc Software Ltd.,
49
50 Ostend, Belgium), and a p value ≤ 0.05 was considered statistically significant.
51
52
53
54
55
56
57
58
59
60

RESULTS

Baseline characteristics of patients were not different between the 36 patients lost to follow-up and the remaining patients. Neither viral late relapse nor re-infection was observed during the follow-up among the 427 included patients and the cohort had a median follow up of 65.2 (IQR: 39.2-76.9) months at June 30, 2021, starting from the SVR achievement.

Baseline demographic, anthropometric and clinical characteristics of the cirrhotic patients divided into two groups according to their favorable (Group 1) and unfavorable (Group 2) Baveno VI status are reported in Table 1; biochemical, virological and hepatologic features of both groups are described in Table 2.

As expected, Group 2 patients showed significantly lower liver synthesis values (albumin 4.1 g/dL [IQR:3.8-4.3] vs 4.3 g/dL [IQR: 4.1-4.6], $p=0.0002$, total cholesterol 130.0 mg/dL [IQR: 130.0-156.8] vs 149.0 mg/dl [IQR: 130.0-167.5], $p=0.001$) and platelet count ($93.0 \times 10^3/\text{mm}^3$ [IQR: 61.0-117.5] vs $192 \times 10^3/\text{mm}^3$ [IQR: 164.0-225.0], $p < 0.0001$); conversely, they showed a higher liver stiffness (21.3 kPa [IQR: 14.8-28.4] vs 14.4 kPa [IQR: 14.1-16.9], <0.0001) as well as more advanced liver disease (MELD 7.0 [IQR: 7.0-9.0] vs 7.0 [IQR: 6.0-7.0], $p < 0.0001$). A statistically significant difference regarding the presence of EV was also found between the 2 groups: only 4.3% of group 1 patients showed baseline EV (3 patients with small EV, 1 patient with F2 EV) compared with 30.1% of group 2 patients (66 patients with small EV, 37 with large EV, $p < 0.0001$). The Baveno VI criteria showed a sensitivity of 96.2% (95% CI: 90.7-99.0), a specificity of 27.50% (CI: 22.7-32.7), a positive predictive value (PPV) of 30.7% (CI: 29.1-32.4) and a negative predictive value (NPV) of 95.7% (CI: 89.2-98.3) in predicting baseline EV.

Baseline PH gastropathy was found in 18 (19.5%) group 1 patients and in 111 (33.1%) group 2 patients ($p=0.002$).

At the end of the follow-up, the overall mortality rate was higher in group 2 patients (7.7% vs 3.2%, $p=0.37$); 8 (2.3%) patients were referred to OLT, none of them belonged to group 1.

1
2 **The first hepatic decompensation event (variceal bleeding, ascites, encephalopathy)**
3
4 **occurred in 1 out of 92 (1%) group 1 patient and in 8/335 (2.4%, p= 0.08) group 2**
5
6 **patients.** Overall, 3/92 (3.2%) patients in group 1 developed HCC during follow-up compared
7
8 to 44/335 (13.1%) in group 2 (p= 0.01). **Follow-up was censored,in patients developing**
9
10 **HCC, therefore LRE after HCC development were not recorded.**
11
12
13
14

15 **EV variations**

16 1) No EV at baseline

17
18 The incidence of “de novo” EV according to baseline Baveno VI status is reported in Figure 2.
19
20 None out of 88 cirrhotics belonging to group 1 without EV at baseline showed EV at 3-year
21
22 follow-up endoscopy compared with 15/232 (6.5%, p= 0.02) of group 2 patients. At the end
23
24 of follow-up, 50 (16.%) out of 305 EV-free patients 3 years after achieving SVR have repeated
25
26 a second upper endoscopy and none showed new onset EV, irrespective of their initial Baveno
27
28 VI status. The Baveno VI criteria had a sensitivity of 96.7% (CI: 90.9-99.3), a specificity of
29
30 26.6% (CI: 22.0-31.7), a PPV of 26.9% (CI: 25.4-28.4), and a NPV of 96.7% (90.6-98.9) in
31
32 predicting EV occurrence during the follow-up.
33
34
35
36
37

38 Table 3 shows the adjusted HR for variables associated to the occurrence of EV in group 2
39
40 patients. By multivariate analysis and after adjustment for several confounding factors (age,
41
42 sex, BMI, obesity, diabetes, metabolic syndrome, albumin,,AST, ALT, GGT levels, co-
43
44 morbidities, Child Pugh Turcotte and MELD staging, liver stiffness), patients who developed
45
46 EV during follow-up were more frequently diabetic and showed a lower platelet count.
47
48
49
50
51

52 2) EV at baseline

53
54 Of the 427 patients included in the study, 107 (25%) showed EV at baseline; 4 (3.7%) belonged
55
56 to Group 1, and 103 (96.3%) to Group 2 (p < 0.0001). During the follow-up, out of 107 patients,
57
58 36 (33.6%) improved, 39 (36.4%) remained unchanged and 32 (29.9%) worsened. In detail,
59
60

1
2 27/69 (39.1%) patients with pre-therapy F1 EV showed varices disappearance (1/3 of group 1),
3
4 in 32 (46.4%) EV remained unchanged (2/3 of group 1) and in 10 (14.5%) worsened. The
5
6 finding of endoscopic worsening in these 10 patients occurred at the 2-year scheduled follow-
7
8 up in 6 (60%) and in 4 (40%) at the second 4-year follow-up; all patients with F1 EV worsening
9
10 belonged to group 2 and demonstrated an unfavorable clinical outcome: 3 (33.3%) developed
11
12 HCC and one patient was referred to OLT.
13

14
15 Among 38 patients with baseline F2/F3 EV, improvement was observed in 9 (23.6%), no
16
17 changes in 7 (18.4%) and worsening in 22 (57.8%). The only patient with baseline large EV
18
19 belonging to group 1 did not show significant EV changes throughout the follow-up.
20
21

22 Overall, variceal worsening was observed only among group 2 patients (29.9% vs 0%, p=
23
24 0.001).
25

26
27 We were not able to identify independent factors associated with PH progression by using the
28
29 Cox Proportional Hazards Model (Table 4).
30
31

32 33 34 **Change of Baveno VI status**

35
36 A worsening in Baveno VI status was found in 7/92 (7.6%, p= 0.12) group 1 patients within a
37
38 median period of 20.2 months (IQR: 6.2- 44.8) and was determined in all patients by the
39
40 decrease of the platelet count below the threshold of $150.000/\text{mm}^3$, only two patients also
41
42 showing an increase in liver stiffness above 20 kPa by TE measurement. By univariate
43
44 regression analysis (multiple Cox regression analysis was not feasible due to the low number
45
46 of worsened patients), we observed that obesity (HR = 3.85, 95% CI: 1.10-22.50, p = 0.04) was
47
48 significantly associated to the unfavorable change.
49
50

51
52 On the other hand, albumin level $> 4 \text{ g / dL}$ was found to be a protective factor (HR = 0.10,
53
54 95% CI: 0.01-0.51, p = 0.008). Of those 7 patients, one (14.2%) died due to myocardial
55
56 infarction and one (14.2%) showed recurrent episodes of ascites. One of them (14.2%) showed
57
58
59
60

1
2 baseline EV which did not worsen during the endoscopic follow-up; of the remaining 6 patients
3
4 without EV at baseline, none developed EV 3 years after the end of therapy.

5
6 Of the 335 patients in group 2, 118 (35.2%, $p < 0.0001$) became Baveno VI status favorable
7
8 and 15 of them (12.7%) had pre-therapy EV compared to 88/217 (40.5%, $p = 0.02$) patients
9
10 who did not improve their status; of those 15, 5 (33.3%) did not show any significant variceal
11
12 change, 9 (60%) showed an improvement and 1 (6.6%) a worsening compared to - respectively
13
14 - 31 (35.2%), 24 (27.2%) and 33 (37.5%) of 88 patients with baseline EV and no Baveno VI
15
16 status variation ($p = 0.01$). Out of 118 patients showing an improvement in their clinical status,
17
18 103 (87.3%) did not have baseline EV compared with 129/217 (59.4%, $p = 0.03$) cirrhotics with
19
20 no changes: none developed EV throughout the follow-up while in 15/129 (11.6%, $p = 0.04$)
21
22 patients with persisting unfavorable Baveno VI status a progression of PH was observed. The
23
24 independent predictive factors of improvement were BMI < 25 (HR= 2.07, 95% CI: 1.41-3.03,
25
26 $P = 0.0002$) and platelet count $> 100,000/\text{mm}^3$ (HR= 3.64, 95% CI: 2.16-6.13, $p = < 0.0001$)
27
28 (Table 5).
29
30
31
32
33

34 A flow-chart showing the suggested timing of endoscopy based on the dynamic of Baveno VI
35
36 status is reported in Figure 3.
37

38 **Finally, we looked for the diagnostic ability of Baveno VI criteria analyzed at the first**
39 **post-treatment endoscopy and LSM/platelet count in predicting EV, regardless of baseline**
40 **variceal and Baveno VI status. Out of 203 (47.5%) patients maintaining or achieving a**
41 **favorable Baveno VI status, 193 (95.1%) showed no EV, 7 (3.4%) showed F1 EV and 2**
42 **(1.5%) showed VNT compared respectively with 158 (70.5%), 44 (19.6%) and 22 (9.8%)**
43 **of patients with unfavorable Baveno VI status. Post-treatment Baveno VI criteria had a**
44 **sensitivity of 88.0% (95% CI: 68,8 - 97,5), a specificity of 49.8% (95% CI: 44,8 - 54,7), a**
45 **PPV of 9.8 (95% CI: 8,4 - 11,5) and a NPV of 98.5% (95% CI: 95,8 - 99,5) in predicting**
46 **the absence of VNT.**
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Since they were published in 2015 (7), the Baveno VI criteria for the screening of EV have been validated by several studies involving cirrhotic patients of different etiologies (10-12,18-20) while data in cirrhotics who have cleared HCV are still scarce, in particular those regarding the endoscopic follow-up (12-14).

According to our data, the Baveno VI criteria can safely rule out VNT in HCV-positive cirrhotic patients with SVR, sparing about 21% screening endoscopies and missing only 1.0% of VNT, confirming what has already been published.

What it is new here is the validation of the Baveno VI guidelines for the endoscopic surveillance in cured patients. The Baveno VI criteria regarding patients with initial favorable status obtaining the removal of the aetiological factor (in this case, recovery from HCV infection) recommend clinical monitoring only (by yearly TE and platelet count); if liver stiffness increases or platelet count declines, these patients should undergo endoscopy (7). In our study, no patients in group 1 developed EV during the follow-up, even if showing Baveno VI status worsening.

Patients showing baseline unfavorable status having no EV and co-morbidities who achieve SVR should undergo surveillance endoscopy at three year intervals; in our series, 6.5% of group 2 patients without EV at baseline developed EV 3 years after obtaining SVR. However, “de novo” EV were not observed in patients showing improvement in their Baveno VI status indicating a potential consisting number of spared endoscopies.. Conversely, EV development was mainly found among patients with metabolic co-morbidities such as diabetes.

In patients with small EV at baseline and no-comorbidities obtaining SVR, surveillance endoscopy should be repeated at two year intervals. In our study, about 65% of patients with pre-therapy F1 EV remained unchanged or worsened throughout the follow-up, confirming previous studies (4-6) which reported persistence of CSPH in the majority of HCV-positive cirrhotic patients despite HCV clearance by DAAs. Improvement in Baveno VI status was not

1
2 helpful in distinguishing patients who showed variceal amelioration as more than 40% of
3
4 patients with pre-therapy EV who changed their initial unfavorable status maintained or
5
6 worsened CSPH. Thus, this finding validates the timing of endoscopic surveillance proposed
7
8 by current guidelines, even in the specific setting of cured HCV-positive patients. In particular,
9
10 the necessity of continuing endoscopic surveillance is further stressed by the variceal
11
12 worsening observed in 4 patients at the second endoscopic control, 4 years after achieving
13
14 SVR.
15
16

17
18 Our data confirm the results of a French multicentre study (12) where 891 cirrhotic patients of
19
20 different origins with and without viral suppression were followed-up for about 6 years. In the
21
22 subgroups analysis, 4.1% of patients without pre-therapy EV and showing viral suppression
23
24 developed EV in the follow-up compared to 4.6% found in our study, while 14.8% of cured
25
26 patients with baseline F1 EV showed a worsening in CSPH compared with 14.5% in our series.
27
28 Similarly to what reported by Thabut et al. (12), improvement in Baveno VI status had a
29
30 beneficial impact on the PH progression but we were able to show that the clinical benefit can
31
32 be safely translated into significant reduction of follow-up endoscopies only in patients with
33
34 pre-therapy unfavorable Baveno VI status and without baseline EV ameliorating their status
35
36 during the follow-up.
37
38

39
40 Moreover, we showed that the absence of PH progression in this subgroup of patients is
41
42 maintained over the long-term as no patients without EV at baseline and at 3-year follow-up
43
44 endoscopy developed EV at 6-year control endoscopy. This finding validates the AGA
45
46 recommendations (15) which suggest no further surveillance endoscopy if EV are not found on
47
48 prior screening examination and after 2-3 years. On the other hand, we cannot confirm the
49
50 AGA conclusions regarding patients with pre-therapy small EV; according to Jacobson et al.
51
52 (15) they can safely avoid further surveillance endoscopy if the F1 EV are unchanged or smaller
53
54 at 2-3 years after SVR achievement. According to our data, a not negligible number of patients
55
56 with baseline F1 EV developed VNT at 4-year follow-up endoscopy, suggesting to not let our
57
58
59
60

1
2 guard down in this particular subgroup of patients.. This recommendation is even more
3
4 stringent if patients with baseline large EV are considered, as about 48% of them showed a
5
6 worsening in size and aspect needing band ligation, 28% remained unchanged and only 24%
7
8 improved.
9

10
11 The strengths of our study are the prospective design with long-term follow-up, the
12
13 predetermined schedule for surveillance endoscopy and TE, the restricted and homogeneous
14
15 pool of endoscopists reducing the risk of interobserver variability regarding the EV grading.
16
17

18
19 A limitation of this study is the relatively high number of excluded patients not complying with
20
21 the endoscopic follow-up or not fit for TE; for this reason, we have to keep in mind that the
22
23 Baveno VI criteria cannot be applicable to all patients. Moreover, despite their capacity of
24
25 ruling out VNT, the Baveno VI criteria allow to safely avoid only about 25% of screening
26
27 endoscopies. We could obtain a larger number of spared endoscopies, if we adopted the
28
29 expanded Baveno VI criteria (8) but their generalized applicability is still matter of debate
30
31 (13,18,21).
32
33

34
35 Finally, at variance with our study design which adopted pre-treatment parameters to stratify
36
37 the patients, recent studies (22,23) showed that a post-treatment algorithm combining simple
38
39 serum markers (albumin, von Willebrand/platelet count ratio) with TE enables a reliable risk
40
41 stratification for development of hepatic decompensation after SVR. Moreover, other
42
43 noninvasive tests such as laboratory tests, spleen elastography, magnetic resonance-based
44
45 techniques and subharmonic aided pressure estimation (SHAPE) (24) alone or in combination
46
47 seem promising approaches in evaluating CSPH but are still awaiting validation.
48
49

50
51 In conclusion, our findings confirm that HCV-positive cirrhotic patients achieving SVR and
52
53 having persisting favorable Baveno VI status can safely avoid endoscopic screening and
54
55 surveillance. Patients with unfavorable Baveno VI status and no pre-therapy EV who change
56
57 their status may suspend endoscopic surveillance. Patients with pre-therapy EV should
58
59 maintain endoscopic follow-up due to the persistence of CSPH in the majority of them.
60

REFERENCES

- 1) Moon AM, Green PK, Rockey DC, Berry K, Ioannou GN. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. *Aliment Pharmacol Ther* 2020 51: 364-373
- 2) Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. *J Viral Hepat* 2017 24: 823-831
- 3) Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. *Aliment Pharmacol Ther* 2017 45: 139-149
- 4) Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer AF et al. Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy. *Hepatology* 2020 71: 1023-1036
- 5) Lens S, Baiges A, Alvarado-Tapias A, Llop E, Martinez J, Fortea JI et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. *J Hepatol* 2020 73: 1415-1424
- 6) Diez C, Berenguer J, Ibanez-Samaniego L, Llop, Perez-Latorre L, Catalina MV et al. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis. *Clin Infect Dis* 2020 71: 2726-2729
- 7) De Franchis R. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015 63: 743-752
- 8) Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. *Hepatology* 2017 66: 1980-1988
- 9) Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2017 65: 310-335
- 10) Maurice JB, Brodtkin E, Arnold F et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. *J Hepatol* 2016 65: 899-905
- 11) Marot A, Trepo E, Doerig C et al. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. *Liver Int* 2017 37: 707-716
- 12) Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. *Gastroenterology* 2019 156: 997-1009
- 13) Giannini EG, De Maria C, Crespi M, Demarzo MG, Fazio V, Grasso A et al. Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. *Eur J Clin Invest* 2020;50:e13231. <https://doi.org/10.1111/eci.13231>
- 14) Puigvehi M, Londono MC, Torras X, Lorente S, Vergara M, Morillas RM et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. *J Gastroenterol* 2020 55: 205-216
- 15) Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute clinical practice update-expert review: care of patients who have achieved a sustained

- 1
2 virologic response after antiviral therapy for chronic hepatitis C infection.
3 Gastroenterology 2017 152: 1578-1587
- 4 16) Pawlotsky JM, Aghemo A, Back D et al. EASL recommendations on treatment of
5 Hepatitis C 2015. J Hepatol 2015 63: 199-236
- 6 17) Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, Kobayashi M.
7 Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointestinal
8 Endoscopy 1981 27: 213-218. DOI: 10.1016/s0016-5107(81)73224-3.
- 9
10
11 18) Bae J, Sinn DH, Kang W et al. Validation of the Baveno VI and the expanded Baveno
12 VI criteria to identify patients who could avoid screening endoscopy. Liver Int 2018 38:
13 1442-1448
- 14
15 19) Nahon P, Bourcier V, Layese R et al. Eradication of hepatitis C virus infection in
16 patients with cirrhosis reduces risk of liver and non-liver complications.
17 Gastroenterology 2017 152: 142-156
- 18 20) Stafylidou M, Paschos P, Katsoula A, Malandris K, Ioakim K, Bekiari E et al.
19 Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk
20 varices in patients with chronic liver diseases: a systematic review and meta-analysis.
21 Clin Gastroenterol Hepatol 2019 17: 1744-1755
- 22 21) De Franchis R. The changing scenario of screening and surveillance of esophageal
23 varices. Gastroenterology 2019 156: 864-866
- 24 22) Pons M, Rodriguez-Tajes S, Esteban JI, Marino Z, Vargas V, Lens S et al. Non-invasive
25 prediction of liver-related events in patients with HCV-associated compensated
26 advanced chronic liver disease after oral antivirals. J Hepatol 2020 72: 472-480
- 27 23) Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zaretto A et al. Non-
28 invasive risk stratification after HCV eradication in patients with advanced chronic liver
29 disease. Hepatology 2021 73: 1275-1289
- 30 24) Vuille-Lessard E, Rodrigues SG, Berzigotti A. Noninvasive detection of clinically
31 significant portal hypertension in compensated advanced chronic liver disease. Clin
32 Liver Dis 2021 25: 253-289
- 33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline epidemiological and clinical characteristics of 427 patients included.

	Favorable Baveno VI status* N= 92 (21.5%) Group 1	Unfavorable Baveno VI status§ N= 335 (78.5%) Group 2	P
Age (years), median [IQR]	60 [52-69.5]	61 [54 - 71]	0.31
Males, n (%)	55 (59.8%)	199 (59.4%)	0.99
Females, n (%)	37 (40.2%)	136 (40.6%)	
Ethnicity			0.02
Caucasian, n (%)	87 (94.6%)	331 (98.8%)	
African, n (%)	5 (5.4%)	4 (1.2%)	
BMI, median [IQR]	24.9 [23.0-28.5]	24.9 [23.0-27.5]	0.67
Abnormal waist circumference, n (%)	40 (43.5%)	128 (38.2%)	0.36
Obese patients, n (%)	10 (10.9%)	34 (10.1%)	0.84
Smoking status			0.172
Never, n (%)	80 (87.0%)	307 (91.6%)	
Past or current smokers, n (%)	12 (13.0%)	28 (8.4%)	
Alcohol intake			0.09
No, n (%)	87 (94.6%)	328 (97.9%)	
Yes, n (%)	5 (5.4%)	7 (2.1%)	
Diabetes, n (%)	13 (14.1)	65 (19.4)	0.25
Metabolic syndrome, n (%)	24 (26.1%)	83 (24.8%)	0.80
Arterial hypertension, n (%)	38 (41.3%)	137 (37.9%)	0.55
Cardiovascular diseases, n (%)	18 (19.6%)	58 (17.3%)	0.62
Kidney diseases, n (%)	6 (6.5%)	8 (2.4%)	0.05
Previous NHL, n (%)	9 (9.8%)	46 (13.7%)	0.31
Previous non-hematological neoplasia, n (%)	3 (3.3%)	7 (2.1%)	0.51
Use of NSBB at inclusion, n (%)	1 (1.1)	36 (10.8)	0.003
Sofosbuvir-based treatment, n (%)	64 (69.5)	279 (82.0)	0.09

1
2 *platelet count $>150.000/\text{mm}^3$ and $\text{TE}<20$ KPa
3 §platelet count $\leq 150.000/\text{mm}^3$ and/or $\text{TE}\geq 20$ KPa
4

5 TE, transient elastography; IQR, Inter Quartile Range; BMI, body mass index; NHL, Non-
6 Hodgkin's Lymphoma.; NSBB, non-selective beta blockers (propranolol or nadolol)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table 2. Baseline biochemical, virologic and liver-related characteristics of 427 patients included.

	Favorable Baveno VI status* N= 92 (21.5%) Group 1	Unfavorable Baveno VI status§ N= 335 (78.5%) Group 2	P
ALT (IU/mL), median [IQR]	67.0 [44.0-119.0]	70.0 [52.0-113.8]	0.46
GGT (IU/mL), median [IQR]	72.0 [35.5-125.0]	60.0 [48.0-98.8]	0.67
Albumin (g/dL), median [IQR]	4.3 [4.1-4.6]	4.1 [3.8-4.3]	0.0002
Total cholesterol (mg/dL), median [IQR]	149.0 [130.0-167.5]	130.0 [130.0-156.8]	0.001
HDL (mg/dL), median [IQR]	40.0 [31.5-50.0]	50.0 [40.0-50.0]	0.06
Triglycerides (mg/dL), median [IQR]	95.0 [76.5-114.5]	100.0 [80.0-106.8]	0.75
Platelets count (x10³/mm³), median [IQR]	192[164.0-225.0]	93.0 [61.0-117.0]	<0.0001
Platelets count (x10³/mm³), n (%)			
≤150	0 (0)	299 (89.3)	
>150	92 (100)	36 (10.7)	<0.0001
Liver stiffness (kPa), median [IQR]	14.4 [14.0-16.9]	21.3 [14.8-28.4]	<0.0001
Liver stiffness <20 kPa (n %)	92 (100)	147 (43.9)	<0.0001
Child-Turcotte-Pugh score			
A, n (%)	91 (98.9)	320 (95.5)	
B, n (%)	1 (1.1)	15 (4.5)	0.139
MELD score, median [IQR]	7.0 [6.0-7.0]	7.0 [7.0-9.0]	<0.0001
MELD <10, n (%)	88 (95.7)	286 (78.4)	
MELD 10-15, n (%)	3 (3.2)	71 (19.4)	0.006
MELD >15, n (%)	1 (1.1)	8 (2.2)	
Esophageal varices			
No, n (%)	88 (95.7)	232 (69.2)	
Grade 1, n (%)	3 (3.3)	67 (20.0)	<0.0001
Grade 2 or 3, n (%)	1 (1.0)	36 (10.8)	
Portal hypertensive gastropathy, n (%)	17 (17.9)	141 (42.1)	<0.0001

*platelet count >150.000/mm³ and TE<20 KPa

§platelet count ≤150.000/mm³ and/or TE≥20 KPa

1
2 TE, transient elastography; IQR, Inter Quartile Range; ALT, alanine aminotransferase; GGT,
3 gamma glutamyl transpeptidase; HDL, High-density lipoprotein; kPa, kilopascal; MELD,
4 Model of End Stage Liver Disease.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table 3. Association between baseline characteristics and development of EV in patients with unfavorable Baveno VI status and without EV at baseline.

Characteristics	Hazard ratio (95% CI)			
	Univariate	p	Multivariate	p
Age >65 years	1.01 (0.97-1.07)	0.46	1.07 (0.98-1.15)	0.12
Male gender	0.16 (0.02-1.12)	0.70	0.91 (0.25-3.38)	0.07
African ethnicity	0.22 (0.03-1.68)	0.15	0.23 (0.01-1.99)	0.19
Normal waist circumference	0.96 (0.89-1.03)	0.21	0.751 (0.55-1.02)	0.07
Obesity	1.94 (0.44-8.60)	0.39	1.89 (0.12-82.2)	0.51
BMI <25	0.65 (0.23-1.83)	0.41	0.74 (0.14-4.02)	0.72
Alcohol intake	N.F.*		N.F.*	
Metabolic syndrome	0.46 (0.10-2.03)	0.30	0.40 (0.09-2.76)	0.09
Diabetes	1.16 (0.33-4.11)	0.82	2.77 (0.88-35.87)	0.02
Arterial hypertension	1.49 (0.53-4.19)	0.45	10.46 (2.26-86,56)	0.08
Cardiovascular diseases	0.45 (0.06-3.39)	0.44	0.13 (0.006-3.06)	0.21
Kidney disease	N.F.*		N.F.*	
Neuropathy	N.F.*		N.F.*	
Previous NHL	2.24 (0.71-7.06)	0.17	2.09 (0.34-12.85)	0.43
Previous non-haematological neoplasia	3.31 (0.43-25.45)	0.25	75.59 (0.02-3161.93)	0.31
Liver stiffness > 25 kPa	1.004 (0.99-1.02)	0.55	1.01 (0.99-1.03)	0.40
MELD score <10	0.25 (0.08-0.73)	0.01	0.12 (0.02-0.88)	0.04
Child-Turcotte-Pugh score B	1.47 (0.19-11.35)	0.71	N.F.*	
ALT >ULN	1.003 (0.996-1.01)	0.35	1.01 (0.999-1.02)	0.06
AST >ULN	1.002 (0.992-1.01)	0.69	0.99 (0.97-1.004)	0.13
GGT >ULN	0.999 (0.99-1.004)	0.76	0.997 (0.99-1.006)	0.48
Platelet count >100000/mm ³	0.18 (0.06-0.58)	0.004	0.15 (0.02-0.94)	0.04
Albumin >4 g/dL	0.31 (0.11-0.87)	0.03	0.45 (0.06-3.19)	0.42

*N.F.: not feasible.

EV, esophageal varices; CI, confidence interval; BMI, body mass index; NHL, Non-Hodgkin lymphoma; MELD, model for end stage liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; ULN, upper limit of normal

Table 4. Association between baseline characteristics and EV worsening in patients with pre-therapy EV and unfavorable Baveno VI status.

Characteristics	Hazard ratio (95% CI)			
	Univariate	p	Multivariate	p
Age >65 years	1.03 (0.995-1.07)	0.09	1.06 (0.99-1.11)	0.05
Male gender	0.52 (0.24-1.13)	0.10	1.61 (0.17-1.37)	0.41
Normal waist circumference	1.002 (0.97-1.04)	0.93	1.001 (0.94-1.06)	0.98
Obesity	0.70 (0.32-1.51)	0.36	2.12 (0.56-.02)	0.27
BMI <25	0.78 (0.39-1.54)	0.47	0.61 (0.56-1.96)	0.41
Alcohol intake	N.F.*		N.F.*	
Metabolic syndrome	1.001 (0.40-2.47)	0.99	2.27 (0.28-18.66)	0.44
Diabetes	0.96 (0.39-2.36)	0.93	1.36 (0.25-7.43)	0.72
Arterial hypertension	1.02 (0.49-2.11)	0.97	0.79 (0.27-2.34)	0.67
Cardiovascular diseases	1.45 (0.59-3.58)	0.42	0.64 (0.18-2.24)	0.48
Kidney disease	N.F.*		N.F.*	
Neuropathy	N.F.*		N.F.*	
Previous NHL	1.53 (0.52--4.47)	0.44	2.96 (0.78-11.20)	0.11
Previous non-haematological neoplasia	N.F.*		N.F.*	
Liver stiffness > 25 kPa	1.03 (1.006-1.06)	0.01	1.04 (0.99-1.08)	0.05
MELD score <10	0.24 (0.11-0.50)	0.001	0.35 (0.12-1.03)	0.06
Child-Turcotte-Pugh score B	2.93 (0.97-8.84)	0.06	3.03 (0.48-19.23)	0.24
ALT >ULN	0.998 (0.99-1.005)	0.58	0.98 (0.96-1.005)	0.12
AST >ULN	1.002 (0.99-1.01)	0.63	1.03 (0.99-1.06)	0.05
GGT >ULN	0.99 (0.99-1.002)	0.13	0.99 (0.98 – 1.007)	0.41
Platelet count >100000/mm ³	0.35 (0.13 – 0.92)	0.03	0.36 (0.11-1.21)	0.10
Albumin >4 g/dL	0.48 (0.21-1.08)	0.08	0.35 (0.15-3.34)	0.20

*N.F.: not feasible.

EV, esophageal varices; CI, confidence interval; BMI, body mass index; NHL, Non-Hodgkin lymphoma; MELD, model for end stage liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; ULN, upper limit of normal

Table 5. Features associated with Baveno VI status improvement in patients with unfavorable Baveno VI status prior to therapy.

Features	Hazard ratio (95% CI)			
	Univariate	p	Multivariate	p
BMI <25	1.86 (1.28-2.71)	0.001	2.07 (1.41-3.03)	0.0002
MELD score <10	2.31 (1.13-4.74)	0.02	1.29 (0.58 – 2.84)	0.53
Pre-therapy EV	0.53 (0.35-0.81)	0.003	0.71 (0.46-1.11)	0.13
Platelet count >100000/mm³	3.55 (2.19-5.74)	<0.0001	3.64 (2.16-6.13)	<0.0001
Albumin >4 g/dL	1.34 (0.90-2.00)	0.15	0.70 (0.45-1.09)	0.13

CI, confidence interval; BMI, body mass index; MELD, model for end stage liver disease; EV, esophageal varices;

1
2
3 LEGENDS
4
5

6 Figure 1. Flow of the recruited patients
7


8 Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HIV, human
9 immunodeficiency virus; TE, transient elastography; OLT, orthotopic liver transplantation;
10
11
12
13 DAAs, direct-acting antiviral agents.
14
15
16
17

18 Figure 2. The Kaplan-Meier curves showing long-term EV incidence in patients with no
19 baseline EV according to their pre-therapy Baveno VI status.
20
21
22
23
24

25 Figure 3. Flow-chart suggesting need and timing of endoscopy for HCV-positive cirrhotic
26 patients achieving SVR after DAA treatment according to the dynamic of their Baveno VI
27 status.
28
29
30
31

32 Abbreviation: EV, esophageal varices; SVR, sustained virological response.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2





Figure 3



1
2
3
4
5
6
7
8
9

**SCREENING AND SURVEILLANCE OF ESOPHAGEAL VARICES IN PATIENTS
WITH HCV-POSITIVE LIVER CIRRHOSIS SUCCESSFULLY TREATED BY
DIRECT ACTING ANTIVIRAL AGENTS**

10 Running title: Impact of SVR on incidence of esophageal varices in HCV-positive cirrhotics
11 treated by DAAs
12
13
14
15
16

17 Alessia Ciancio, Davide Giuseppe Ribaldone, Rossella Salamone, Mauro Bruno, Stefania
18 Caronna, Wilma Debernardi Venon, Chiara Giordanino, Alessandra Mondardini, Alessandro
19 Musso, Marco Pennazio, Emanuela Rolle, Marco Sacco, Tatiana Sprujevnik, Claudio De
20 Angelis, Giorgio Maria Saracco.
21
22
23
24
25
26
27
28
29

30 Gastro-hepatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
31
32
33
34
35

36 Corresponding author :

37
38 Giorgio Maria Saracco, MD

39 Gastro-hepatology Unit

40 Molinette Hospital, University of Turin

41 Corso Bramante 88

42 10126 Torino, Italy

43 tel.: 39-011-6336397

44 e-mail: giorgiomaria.saracco@unito.it

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ORCID: <http://orcid.org/0000-0001-5310-4143>

Word count (only text): 4213 words.

1
2 **Tables number:** 5
3

4
5 **Figures number:** 3
6
7

8 **Abbreviation list:** HCV, hepatitis C virus; LRE, liver-related events; DAAs, direct-acting
9 antiviral agents; HCC, hepatocellular carcinoma; SVR, sustained virologic response; TE,
10 transient elastography; APRI, aspartate aminotransferase to platelet ratio; OLT, orthotopic liver
11 transplantation; HIV, Human Immunodeficiency Virus; EASL, European Association for the
12 Study of the Liver; BMI, body mass index; WC, waist circumference; DM, type 2 diabetes
13 mellitus; ALT, alanine aminotransferase; APH, alkaline phosphatase; GGT, gamma
14 glutamyltranspeptidase; US, abdominal ultrasound; MELD, model for end-stage liver diseases;
15 IQR, Inter Quartile Range; CI, confidence interval; OR, odds ratio; HR, hazard ratio; EV,
16 esophageal varices; CSPH, Clinically Significant Portal Hypertension; VNT, Varices Needing
17 Treatment
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Data availability statement:** The data that support the findings of this study are available from
36 the corresponding author upon reasonable request.
37
38
39

40 **Author Contributions:** conceptualization, G.M.S.; methodology, D.G.R.; software, M.S,
41 R.S.; validation, D.G.R. and M.S.; formal analysis, D.G.R.; investigation, R.S., S.C., D.G.R.,
42 M.S., M.B., W.D.V., C.G., A.M., M.P.E.R., T.S., C.D.A.; data curation, D.G.R., A.C., M.S.,
43 and G.M.S.; writing—original draft preparation, G.M.S.; writing—review and editing, D.G.R.
44 and M.S.; visualization, A.C., M.S.; supervision, G.M.S.; project administration, G.M.S.
45
46

47 **Permission to reproduce material from other sources:** obtained
48

49 **Potential competing interests:** all authors declare no potential conflicts of interest.
50
51

52
53 **Financial support:** the project has been partially supported by a Gilead Sciences Medical
54 Grant
55

56 **Ethics approval:** obtained
57
58

59 **Patient consent:** obtained
60

ABSTRACT

Background and aims: limited evidence is available to guide hepatologists regarding endoscopic surveillance of esophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted a long-term prospective study on 427 HCV-positive cirrhotic patients successfully treated by Direct Antiviral Agents (DAAs).

Methods: patients were divided into 2 groups according to their baseline Baveno VI status: Group 1 (92, 21.5%, favorable Baveno VI status) and Group 2 (335, 78.5%, unfavorable Baveno VI status). Each patient underwent baseline endoscopy and was endoscopically monitored for a median follow-up of 65.2 months according to Baveno VI recommendations.

Results: 4.3% of group 1 patients showed baseline EV compared with 30.1% of group 2 patients ($p < 0.0001$). No patients belonging to group 1 without baseline EV developed EV at follow-up endoscopy compared with 6.5% in group 2 patients ($p = 0.02$); 69/107 (64.5%) patients with baseline EV showed small varices. During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 ($p = 0.001$). Improvement in Baveno VI status was observed in 118/335 (35.2%, $p < 0.0001$) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up.

Conclusions: HCV-positive cirrhotic patients cured by DAAs showing baseline favorable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients having unfavorable Baveno VI status without baseline EV who improve their status may suspend further endoscopic surveillance.

Lay Summary

- Noninvasive criteria suggested by the Baveno VI and the Baveno VI expanded guidelines avoid screening endoscopies in a significant subset of cirrhotic patients but their application on long-term variceal surveillance in patients achieving sustained virologic response (SVR) by direct acting antiviral agents (DAA) is largely unknown.
- Whether further endoscopic surveillance is required in cirrhotics obtaining SVR with no esophageal varices (EV) on prior screening examination and which is the optimal endoscopic timing in patients with pre-therapy EV is still debated.
- In this study, we showed that patients having persisting favorable Baveno VI status may not undergo endoscopic surveillance while patients with unfavorable Baveno VI status and no baseline EV who improve their status may suspend further endoscopic surveillance.
- Patients with pre-therapy unfavorable Baveno VI status and small VE should maintain follow-up endoscopy at 2-year interval.

INTRODUCTION

Hepatitis C Virus (HCV) – positive cirrhotic patients achieving a sustained virologic response (SVR) by Direct Acting Antiviral Agents (DAAs) show a progressive decrease in portal pressure during follow-up reducing the risk of variceal bleeding (1). However, clinically significant portal hypertension (CSPH) may persist in a significant proportion of them (2-6). This observation has an important clinical impact by influencing our policy of screening and surveillance of esophageal varices (EV) in cured patients. Current guidelines (7-9) recommend the use of noninvasive techniques such as transient elastography (TE) and platelet count to reduce endoscopic screening: patients showing a liver stiffness measurement (LSM) <20 kPa and platelet count >150.000/mm³ can safely avoid endoscopy having a very low risk (<5%) of varices needing treatment (VNT) (10,11). According to the Baveno VI Consensus Workshop, these patients – defined as Baveno VI status favorable - can be safely followed up by yearly repetition of TE and platelet count (7). However, data supporting this recommendation are still scarce (12-14).

What it is still matter of debate is the optimal timing for surveillance endoscopy in cured patients showing unfavorable pre-therapy Baveno VI status. According to the international guidelines (7,9), in compensated patients without co-morbidities and no baseline EV or small varices prior to therapy, endoscopy should be repeated at three and two year intervals respectively. However, strength of recommendation and level of evidence are very low. A recent clinical practice update-expert review (15) by the American Gastroenterological Association (AGA) suggests follow-up endoscopy after 2-3 years in patients with no EV on prior screening examination and no further surveillance if EV are not found; patients with small EV at baseline should undergo follow-up endoscopy after 2-3 years and no further surveillance if EV unchanged or smaller.

1
2 In order to individuate the optimal type, frequency and length of EV surveillance in relation to
3
4 the clinical status of the patients, we conducted a long-term prospective study on HCV-positive
5
6 patients with compensated cirrhosis successfully treated by DAAs aiming at monitoring the
7
8 course of EV according to the Baveno VI criteria (7) as well as the impact on portal
9
10 hypertension (PH) exerted by changes of Baveno VI status.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

PATIENTS AND METHODS

This prospective cohort study included all consecutive patients with Child A-B HCV cirrhosis treated by DAAs according to the European Association for the Study of the Liver (EASL) guidelines (16) in the Gastrohepatologic Clinic of Molinette Hospital, Turin, Italy from January 1, 2015 to December 31, 2016. Inclusion criteria were as follows: > 18 years; positive HCV-RNA by polymerase chain reaction (PCR); liver cirrhosis assessed by TE and aspartate aminotransferase (AST) to platelet ratio (APRI) score. Exclusion criteria were: lack of written informed consent, TE not feasible or unreliable measurement, patients on waiting list for orthotopic liver transplant (OLT), post-OLT patients, past or current history of hepatocellular carcinoma (HCC), past or current episodes of ascites and/or encephalopathy, prophylactic banding of EV, previous episodes of variceal bleeding treated by endoscopic banding, concomitant liver diseases such as haemochromatosis, Wilson's disease, drug-related liver disease, autoimmune hepatitis, HBsAg carriership, Human immunodeficiency Virus (HIV) infection, primary biliary cholangitis, alpha-1-antitrypsin deficiency. Out of 596 consecutive patients considered for treatment with DAAs, 478 (80.2%) fulfilled the above mentioned criteria and agreed to participate; 15 out of 478 recruited patients (3.1%) did not achieve SVR and were excluded from the study. Out of 463 sustained responders, 36 (7.8%) were lost to follow up. Therefore, the final analysis was performed in 427 cirrhotic patients with SVR. Patients' flow is reported in Figure 1.

At baseline, a complete medical history and physical examination was undertaken and the following data were obtained from each patient: age, gender, ethnicity, smoking habits, alcohol intake, body mass index (BMI), waist circumference (WC), duration of HCV infection, relevant co-morbidities. The following data on laboratory parameters were also recorded to define baseline characteristics: complete blood count, routine liver biochemistry (alanine aminotransferase [ALT] and AST, total bilirubin, albumin, alkaline phosphatase [APH], gamma glutamyltranspeptidase [GGT]) international normalized ratio [INR]), creatinine,

1
2 fasting plasma glucose [FPG], total cholesterol and HDL, triglycerides, HCV genotype and
3
4 viral load [AmpliPrep®/COBAS Taqman® HCV test, Roche Diagnostics, Basel, Switzerland].

5
6
7 Severity of liver fibrosis was determined within 3 months prior to inclusion into the study by
8
9 non-invasive (AST to platelet ratio [APRI] and TE) methods. Cut-offs used to diagnose
10
11 cirrhosis were > 1.5 for APRI test and ≥ 14 kPa for TE. The reliability criteria for LSM were
12
13 as follows: 10 valid measurements achieved with a success number $\geq 60\%$ and an interquartile
14
15 range-to-median ratio $\leq 30\%$. A minimum of 3 hours fasting was required. Abdominal
16
17 ultrasound (US) was performed in each patient at baseline in order to exclude HCC.

18
19
20
21 Patients were stratified according to the Child-Turcotte-Pugh classification and Model for End-
22
23 Stage Liver Disease [MELD]; LSM and platelet count was obtained in each patient within 3
24
25 months before starting treatment in order to establish the Baveno VI status (7).

31 **Follow-up**

32
33
34 When the study was approved, upper endoscopy was still mandatory in cirrhotic patients to
35
36 assess the presence and grading of esophageal/gastric varices. For this reason, all patients
37
38 underwent oesophagogastroduodenoscopy within 3 months before starting therapy; patients
39
40 with F2/F3 EV were given Non-Selective Beta Blockers (NSBB). If intolerant or not
41
42 responding to NSBB, patients underwent prophylactic banding of EV and were excluded from
43
44 the study. In order to validate the surveillance timing suggested by Baveno VI Consensus
45
46 Workshop in a population composed by HCV-positive compensated cirrhotics successfully
47
48 treated by DAAs, we recommended the following endoscopic approach: 1) surveillance
49
50 endoscopy at three year intervals in patients with no varices at baseline endoscopy 2)
51
52 surveillance endoscopy at two year intervals in patients with small varices (F1) at baseline
53
54 endoscopy. Cirrhotic patients with large varices (F2/F3) on NSBB prophylaxis were planned
55
56 to undergo yearly endoscopy. Variceal worsening (or PH progression) was defined as the
57
58
59
60

1
2 occurrence of EV in patients with no prior EV or large EV in previous carriers of small EV, the
3
4 occurrence of grade 3 EV in patients with baseline grade 2 EV, or the onset of a variceal
5
6 bleeding.
7

8
9 Control visits were planned at 6-months intervals after achieving SVR and patients were
10
11 followed until OLT, death or until the end of June 2021. Patients were also censored at the
12
13 moment of HCC occurrence. Mortality was registered as liver-related or non-liver related. At
14
15 each control visit, medical history and physical examination were performed; liver function
16
17 tests, platelet determination, HCV-RNA assessment and liver US were recorded as well as the
18
19 occurrence of liver related events [LRE] (ascites, variceal bleeding, hepatic encephalopathy,
20
21 HCC).
22
23

24
25 More than 90% of all endoscopic procedures were performed by a pool of experienced
26
27 endoscopists (A.M., W.D.V., C.G., S.C., C.D.A., M.B., E.R., M.P., A.M, T.S..) working in our
28
29 Endoscopy Unit and adopting the Beppu's classification of EV (17). All of them were blinded
30
31 to the study design. For the aims of the study, EV were defined as: 1) no EV 2) small EV
32
33 corresponding to grade 1 EV no needing treatment 3) large EV corresponding to grade 2/3
34
35 EV needing treatment.
36
37
38

39
40 In order to check for worsening/improvement of their Baveno VI status, all patients underwent
41
42 at least 1 LSM by TE during follow-up at the time of repetition of endoscopy, at variance with
43
44 the Baveno VI recommendations suggesting yearly TE; the number of LSM reached 2 (IQR: 1-
45
46 3) and the median delay between measurements were 24.8 months (IQR: 12.4-36.6). Platelet
47
48 count was obtained during the 6-month control visits planned throughout the follow-up
49
50 (number: 10 [IQR: 8-12]).
51
52

53
54 An improvement in Baveno VI status was defined as an increase in the platelet count above
55
56 $150.000/\text{mm}^3$ and a decrease of LSM to <20 kPa in cirrhotics with a baseline unfavorable status.

57
58 A worsening of Baveno VI status was defined as the occurrence of either platelet count
59
60

1
2 $\leq 150.000/\text{mm}^3$ or LSM ≥ 20 kPa during follow-up in patients with a baseline favorable Baveno
3
4 VI status.
5

6
7 The study was performed in accordance with the principles of the 1975 Declaration of Helsinki
8
9 and approved by our local ethics committee (Comitato Etico Interaziendale Città della Salute e
10
11 della Scienza di Torino, Turin, Italy); written informed consent was obtained from all patients.
12
13

14 15 16 **Statistical analysis**

17
18 Continuous variables were reported as median (Inter Quartile Range [IQR] and 95%
19
20 confidence interval [CI]) or geometric mean according to the data distribution. Normality was
21
22 checked by the D'Agostino–Pearson test. Categorical variables were reported as number and
23
24 percentage. Comparison of continuous variables between independent groups was performed
25
26 by the Mann–Whitney test or independent samples t-test according to data distribution;
27
28 comparison between paired measurements was performed by the Wilcoxon test or paired
29
30 samples t-test according to data distribution. Regarding the dichotomous categorical variable,
31
32 a Chi-squared test or McNemar test were performed for unpaired or paired analysis,
33
34 respectively. The association between variables was assessed by Cox proportional-hazards
35
36 regression; the strength of association was reported as hazards ratio (H.R.) and 95% CI,
37
38 accordingly. The rate of favorable and unfavorable Baveno VI status patients free from varices
39
40 has been presented by using Kaplan-Meier curves and the statistical differences were tested by
41
42 the Mantel-Cox method. Patients not developing EV were censored at last visit or at the
43
44 moment of OLT, HCC occurrence or at the date of death.

45
46 All statistical analyses were performed using MedCalc® v.18.9.1 (MedCalc Software Ltd.,
47
48 Ostend, Belgium), and a p value ≤ 0.05 was considered statistically significant.
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Baseline characteristics of patients were not different between the 36 patients lost to follow-up and the remaining patients. Neither viral late relapse nor re-infection was observed during the follow-up among the 427 included patients and the cohort had a median follow up of 65.2 (IQR: 39.2-76.9) months at June 30, 2021, starting from the SVR achievement.

Baseline demographic, anthropometric and clinical characteristics of the cirrhotic patients divided into two groups according to their favorable (Group 1) and unfavorable (Group 2) Baveno VI status are reported in Table 1; biochemical, virological and hepatologic features of both groups are described in Table 2.

As expected, Group 2 patients showed significantly lower liver synthesis values (albumin 4.1 g/dL [IQR:3.8-4.3] vs 4.3 g/dL [IQR: 4.1-4.6], $p=0.0002$, total cholesterol 130.0 mg/dL [IQR: 130.0-156.8] vs 149.0 mg/dl [IQR: 130.0-167.5], $p=0.001$) and platelet count ($93.0 \times 10^3/\text{mm}^3$ [IQR: 61.0-117.5] vs $192 \times 10^3/\text{mm}^3$ [IQR: 164.0-225.0], $p < 0.0001$); conversely, they showed a higher liver stiffness (21.3 kPa [IQR: 14.8-28.4] vs 14.4 kPa [IQR: 14.1-16.9], <0.0001) as well as more advanced liver disease (MELD 7.0 [IQR: 7.0-9.0] vs 7.0 [IQR: 6.0-7.0], $p < 0.0001$). A statistically significant difference regarding the presence of EV was also found between the 2 groups: only 4.3% of group 1 patients showed baseline EV (3 patients with small EV, 1 patient with F2 EV) compared with 30.1% of group 2 patients (66 patients with small EV, 37 with large EV, $p < 0.0001$). The Baveno VI criteria showed a sensitivity of 96.2% (95% CI: 90.7-99.0), a specificity of 27.50% (CI: 22.7-32.7), a positive predictive value (PPV) of 30.7% (CI: 29.1-32.4) and a negative predictive value (NPV) of 95.7% (CI: 89.2-98.3) in predicting baseline EV.

Baseline PH gastropathy was found in 18 (19.5%) group 1 patients and in 111 (33.1%) group 2 patients ($p=0.002$).

At the end of the follow-up, the overall mortality rate was higher in group 2 patients (7.7% vs 3.2%, $p=0.37$); 8 (2.3%) patients were referred to OLT, none of them belonged to group 1.

1
2 The first hepatic decompensation event (variceal bleeding, ascites, encephalopathy) occurred
3
4 in 1 out of 92 (1%) group 1 patient and in 8/335 (2.4%, $p= 0.08$) group 2 patients. Overall,
5
6 3/92 (3.2%) patients in group 1 developed HCC during follow-up compared to 44/335 (13.1%)
7
8 in group 2 ($p= 0.01$). Follow-up was censored, in patients developing HCC, therefore LRE after
9
10 HCC development were not recorded.
11
12
13
14

15 **EV variations**

16 1) No EV at baseline

17
18 The incidence of “de novo” EV according to baseline Baveno VI status is reported in Figure 2.
19
20 None out of 88 cirrhotics belonging to group 1 without EV at baseline showed EV at 3-year
21
22 follow-up endoscopy compared with 15/232 (6.5%, $p= 0.02$) of group 2 patients. At the end
23
24 of follow-up, 50 (16.%) out of 305 EV-free patients 3 years after achieving SVR have repeated
25
26 a second upper endoscopy and none showed new onset EV, irrespective of their initial Baveno
27
28 VI status. The Baveno VI criteria had a sensitivity of 96.7% (CI: 90.9-99.3), a specificity of
29
30 26.6% (CI: 22.0-31.7), a PPV of 26.9% (CI: 25.4-28.4), and a NPV of 96.7% (90.6-98.9) in
31
32 predicting EV occurrence during the follow-up.
33
34
35
36
37

38 Table 3 shows the adjusted HR for variables associated to the occurrence of EV in group 2
39
40 patients. By multivariate analysis and after adjustment for several confounding factors (age,
41
42 sex, BMI, obesity, diabetes, metabolic syndrome, albumin, AST, ALT, GGT levels, co-
43
44 morbidities, Child Pugh Turcotte and MELD staging, liver stiffness), patients who developed
45
46 EV during follow-up were more frequently diabetic and showed a lower platelet count.
47
48
49
50
51

52 2) EV at baseline

53
54 Of the 427 patients included in the study, 107 (25%) showed EV at baseline; 4 (3.7%) belonged
55
56 to Group 1, and 103 (96.3%) to Group 2 ($p < 0.0001$). During the follow-up, out of 107 patients,
57
58 36 (33.6%) improved, 39 (36.4%) remained unchanged and 32 (29.9%) worsened. In detail,
59
60

1
2 27/69 (39.1%) patients with pre-therapy F1 EV showed varices disappearance (1/3 of group 1),
3
4 in 32 (46.4%) EV remained unchanged (2/3 of group 1) and in 10 (14.5%) worsened. The
5
6 finding of endoscopic worsening in these 10 patients occurred at the 2-year scheduled follow-
7
8 up in 6 (60%) and in 4 (40%) at the second 4-year follow-up; all patients with F1 EV worsening
9
10 belonged to group 2 and demonstrated an unfavorable clinical outcome: 3 (33.3%) developed
11
12 HCC and one patient was referred to OLT.
13

14
15 Among 38 patients with baseline F2/F3 EV, improvement was observed in 9 (23.6%), no
16
17 changes in 7 (18.4%) and worsening in 22 (57.8%). The only patient with baseline large EV
18
19 belonging to group 1 did not show significant EV changes throughout the follow-up.
20
21

22 Overall, variceal worsening was observed only among group 2 patients (29.9% vs 0%, p=
23
24 0.001).
25

26
27 We were not able to identify independent factors associated with PH progression by using the
28
29 Cox Proportional Hazards Model (Table 4).
30
31

32 33 34 **Change of Baveno VI status**

35
36 A worsening in Baveno VI status was found in 7/92 (7.6%, p= 0.12) group 1 patients within a
37
38 median period of 20.2 months (IQR: 6.2- 44.8) and was determined in all patients by the
39
40 decrease of the platelet count below the threshold of $150.000/\text{mm}^3$, only two patients also
41
42 showing an increase in liver stiffness above 20 kPa by TE measurement. By univariate
43
44 regression analysis (multiple Cox regression analysis was not feasible due to the low number
45
46 of worsened patients), we observed that obesity (HR = 3.85, 95% CI: 1.10-22.50, p = 0.04) was
47
48 significantly associated to the unfavorable change.
49
50

51
52 On the other hand, albumin level $> 4 \text{ g / dL}$ was found to be a protective factor (HR = 0.10,
53
54 95% CI: 0.01-0.51, p = 0.008). Of those 7 patients, one (14.2%) died due to myocardial
55
56 infarction and one (14.2%) showed recurrent episodes of ascites. One of them (14.2%) showed
57
58
59
60

1
2 baseline EV which did not worsen during the endoscopic follow-up; of the remaining 6 patients
3
4 without EV at baseline, none developed EV 3 years after the end of therapy.
5

6 Of the 335 patients in group 2, 118 (35.2%, $p < 0.0001$) became Baveno VI status favorable
7 and 15 of them (12.7%) had pre-therapy EV compared to 88/217 (40.5%, $p = 0.02$) patients
8 who did not improve their status; of those 15, 5 (33.3%) did not show any significant variceal
9 change, 9 (60%) showed an improvement and 1 (6.6%) a worsening compared to - respectively
10 - 31 (35.2%), 24 (27.2%) and 33 (37.5%) of 88 patients with baseline EV and no Baveno VI
11 status variation ($p = 0.01$). Out of 118 patients showing an improvement in their clinical status,
12 103 (87.3%) did not have baseline EV compared with 129/217 (59.4%, $p = 0.03$) cirrhotics with
13 no changes: none developed EV throughout the follow-up while in 15/129 (11.6%, $p = 0.04$)
14 patients with persisting unfavorable Baveno VI status a progression of PH was observed. The
15 independent predictive factors of improvement were BMI < 25 (HR= 2.07, 95% CI: 1.41-3.03,
16 $P = 0.0002$) and platelet count $> 100,000/\text{mm}^3$ (HR= 3.64, 95% CI: 2.16-6.13, $p = < 0.0001$)
17 (Table 5).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 A flow-chart showing the suggested timing of endoscopy based on the dynamic of Baveno VI
35 status is reported in Figure 3.
36
37

38 Finally, we looked for the diagnostic ability of Baveno VI criteria analyzed at the first post-
39 treatment endoscopy and LSM/platelet count in predicting EV, regardless of baseline variceal
40 and Baveno VI status. Out of 203 (47.5%) patients maintaining or achieving a favorable
41 Baveno VI status, 193 (95.1%) showed no EV, 7 (3.4%) showed F1 EV and 2 (1.5%) showed
42 VNT compared respectively with 158 (70.5%), 44 (19.6%) and 22 (9.8%) of patients with
43 unfavorable Baveno VI status. Post-treatment Baveno VI criteria had a sensitivity of 88.0%
44 (95% CI: 68,8 - 97,5), a specificity of 49.8% (95% CI: 44,8 - 54,7), a PPV of 9.8 (95% CI:
45 8,4 - 11,5) and a NPV of 98.5% (95% CI: 95,8 - 99,5) in predicting the absence of VNT.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Since they were published in 2015 (7), the Baveno VI criteria for the screening of EV have been validated by several studies involving cirrhotic patients of different etiologies (10-12,18-20) while data in cirrhotics who have cleared HCV are still scarce, in particular those regarding the endoscopic follow-up (12-14).

According to our data, the Baveno VI criteria can safely rule out VNT in HCV-positive cirrhotic patients with SVR, sparing about 21% screening endoscopies and missing only 1.0% of VNT, confirming what has already been published.

What it is new here is the validation of the Baveno VI guidelines for the endoscopic surveillance in cured patients. The Baveno VI criteria regarding patients with initial favorable status obtaining the removal of the aetiological factor (in this case, recovery from HCV infection) recommend clinical monitoring only (by yearly TE and platelet count); if liver stiffness increases or platelet count declines, these patients should undergo endoscopy (7). In our study, no patients in group 1 developed EV during the follow-up, even if showing Baveno VI status worsening.

Patients showing baseline unfavorable status having no EV and co-morbidities who achieve SVR should undergo surveillance endoscopy at three year intervals; in our series, 6.5% of group 2 patients without EV at baseline developed EV 3 years after obtaining SVR. However, “de novo” EV were not observed in patients showing improvement in their Baveno VI status indicating a potential consisting number of spared endoscopies.. Conversely, EV development was mainly found among patients with metabolic co-morbidities such as diabetes.

In patients with small EV at baseline and no-comorbidities obtaining SVR, surveillance endoscopy should be repeated at two year intervals. In our study, about 65% of patients with pre-therapy F1 EV remained unchanged or worsened throughout the follow-up, confirming previous studies (4-6) which reported persistence of CSPH in the majority of HCV-positive cirrhotic patients despite HCV clearance by DAAs. Improvement in Baveno VI status was not

1
2 helpful in distinguishing patients who showed variceal amelioration as more than 40% of
3
4 patients with pre-therapy EV who changed their initial unfavorable status maintained or
5
6 worsened CSPH. Thus, this finding validates the timing of endoscopic surveillance proposed
7
8 by current guidelines, even in the specific setting of cured HCV-positive patients. In particular,
9
10 the necessity of continuing endoscopic surveillance is further stressed by the variceal
11
12 worsening observed in 4 patients at the second endoscopic control, 4 years after achieving
13
14 SVR.
15
16

17
18 Our data confirm the results of a French multicentre study (12) where 891 cirrhotic patients of
19
20 different origins with and without viral suppression were followed-up for about 6 years. In the
21
22 subgroups analysis, 4.1% of patients without pre-therapy EV and showing viral suppression
23
24 developed EV in the follow-up compared to 4.6% found in our study, while 14.8% of cured
25
26 patients with baseline F1 EV showed a worsening in CSPH compared with 14.5% in our series.
27
28 Similarly to what reported by Thabut et al. (12), improvement in Baveno VI status had a
29
30 beneficial impact on the PH progression but we were able to show that the clinical benefit can
31
32 be safely translated into significant reduction of follow-up endoscopies only in patients with
33
34 pre-therapy unfavorable Baveno VI status and without baseline EV ameliorating their status
35
36 during the follow-up.
37
38

39
40 Moreover, we showed that the absence of PH progression in this subgroup of patients is
41
42 maintained over the long-term as no patients without EV at baseline and at 3-year follow-up
43
44 endoscopy developed EV at 6-year control endoscopy. This finding validates the AGA
45
46 recommendations (15) which suggest no further surveillance endoscopy if EV are not found on
47
48 prior screening examination and after 2-3 years. On the other hand, we cannot confirm the
49
50 AGA conclusions regarding patients with pre-therapy small EV; according to Jacobson et al.
51
52 (15) they can safely avoid further surveillance endoscopy if the F1 EV are unchanged or smaller
53
54 at 2-3 years after SVR achievement. According to our data, a not negligible number of patients
55
56 with baseline F1 EV developed VNT at 4-year follow-up endoscopy, suggesting to not let our
57
58
59
60

1
2 guard down in this particular subgroup of patients.. This recommendation is even more
3
4 stringent if patients with baseline large EV are considered, as about 48% of them showed a
5
6 worsening in size and aspect needing band ligation, 28% remained unchanged and only 24%
7
8 improved.
9

10
11 The strengths of our study are the prospective design with long-term follow-up, the
12
13 predetermined schedule for surveillance endoscopy and TE, the restricted and homogeneous
14
15 pool of endoscopists reducing the risk of interobserver variability regarding the EV grading.
16
17

18
19 A limitation of this study is the relatively high number of excluded patients not complying with
20
21 the endoscopic follow-up or not fit for TE; for this reason, we have to keep in mind that the
22
23 Baveno VI criteria cannot be applicable to all patients. Moreover, despite their capacity of
24
25 ruling out VNT, the Baveno VI criteria allow to safely avoid only about 25% of screening
26
27 endoscopies. We could obtain a larger number of spared endoscopies, if we adopted the
28
29 expanded Baveno VI criteria (8) but their generalized applicability is still matter of debate
30
31 (13,18,21).
32
33

34
35 Finally, at variance with our study design which adopted pre-treatment parameters to stratify
36
37 the patients, recent studies (22,23) showed that a post-treatment algorithm combining simple
38
39 serum markers (albumin, von Willebrand/platelet count ratio) with TE enables a reliable risk
40
41 stratification for development of hepatic decompensation after SVR. Moreover, other
42
43 noninvasive tests such as laboratory tests, spleen elastography, magnetic resonance-based
44
45 techniques and subharmonic aided pressure estimation (SHAPE) (24) alone or in combination
46
47 seem promising approaches in evaluating CSPH but are still awaiting validation.
48
49

50
51 In conclusion, our findings confirm that HCV-positive cirrhotic patients achieving SVR and
52
53 having persisting favorable Baveno VI status can safely avoid endoscopic screening and
54
55 surveillance. Patients with unfavorable Baveno VI status and no pre-therapy EV who change
56
57 their status may suspend endoscopic surveillance. Patients with pre-therapy EV should
58
59 maintain endoscopic follow-up due to the persistence of CSPH in the majority of them.
60

REFERENCES

- 1) Moon AM, Green PK, Rockey DC, Berry K, Ioannou GN. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. *Aliment Pharmacol Ther* 2020 51: 364-373
- 2) Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. *J Viral Hepat* 2017 24: 823-831
- 3) Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. *Aliment Pharmacol Ther* 2017 45: 139-149
- 4) Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer AF et al. Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy. *Hepatology* 2020 71: 1023-1036
- 5) Lens S, Baiges A, Alvarado-Tapias A, Llop E, Martinez J, Fortea JI et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. *J Hepatol* 2020 73: 1415-1424
- 6) Diez C, Berenguer J, Ibanez-Samaniego L, Llop, Perez-Latorre L, Catalina MV et al. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis. *Clin Infect Dis* 2020 71: 2726-2729
- 7) De Franchis R. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015 63: 743-752
- 8) Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. *Hepatology* 2017 66: 1980-1988
- 9) Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2017 65: 310-335
- 10) Maurice JB, Brodtkin E, Arnold F et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. *J Hepatol* 2016 65: 899-905
- 11) Marot A, Trepo E, Doerig C et al. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. *Liver Int* 2017 37: 707-716
- 12) Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. *Gastroenterology* 2019 156: 997-1009
- 13) Giannini EG, De Maria C, Crespi M, Demarzo MG, Fazio V, Grasso A et al. Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. *Eur J Clin Invest* 2020;50:e13231. <https://doi.org/10.1111/eci.13231>
- 14) Puigvehi M, Londono MC, Torras X, Lorente S, Vergara M, Morillas RM et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. *J Gastroenterol* 2020 55: 205-216
- 15) Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute clinical practice update-expert review: care of patients who have achieved a sustained

- 1
2 virologic response after antiviral therapy for chronic hepatitis C infection.
3 Gastroenterology 2017 152: 1578-1587
- 4 16) Pawlotsky JM, Aghemo A, Back D et al. EASL recommendations on treatment of
5 Hepatitis C 2015. J Hepatol 2015 63: 199-236
- 6 17) Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, Kobayashi M.
7 Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointestinal
8 Endoscopy 1981 27: 213-218. DOI: 10.1016/s0016-5107(81)73224-3.
- 9
10
11 18) Bae J, Sinn DH, Kang W et al. Validation of the Baveno VI and the expanded Baveno
12 VI criteria to identify patients who could avoid screening endoscopy. Liver Int 2018 38:
13 1442-1448
- 14
15 19) Nahon P, Bourcier V, Layese R et al. Eradication of hepatitis C virus infection in
16 patients with cirrhosis reduces risk of liver and non-liver complications.
17 Gastroenterology 2017 152: 142-156
- 18 20) Stafylidou M, Paschos P, Katsoula A, Malandris K, Ioakim K, Bekiari E et al.
19 Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk
20 varices in patients with chronic liver diseases: a systematic review and meta-analysis.
21 Clin Gastroenterol Hepatol 2019 17: 1744-1755
- 22 21) De Franchis R. The changing scenario of screening and surveillance of esophageal
23 varices. Gastroenterology 2019 156: 864-866
- 24 22) Pons M, Rodriguez-Tajes S, Esteban JI, Marino Z, Vargas V, Lens S et al. Non-invasive
25 prediction of liver-related events in patients with HCV-associated compensated
26 advanced chronic liver disease after oral antivirals. J Hepatol 2020 72: 472-480
- 27 23) Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zaretto A et al. Non-
28 invasive risk stratification after HCV eradication in patients with advanced chronic liver
29 disease. Hepatology 2021 73: 1275-1289
- 30 24) Vuille-Lessard E, Rodrigues SG, Berzigotti A. Noninvasive detection of clinically
31 significant portal hypertension in compensated advanced chronic liver disease. Clin
32 Liver Dis 2021 25: 253-289
- 33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline epidemiological and clinical characteristics of 427 patients included.

	Favorable Baveno VI status* N= 92 (21.5%) Group 1	Unfavorable Baveno VI status§ N= 335 (78.5%) Group 2	P
Age (years), median [IQR]	60 [52-69.5]	61 [54 - 71]	0.31
Males, n (%)	55 (59.8%)	199 (59.4%)	0.99
Females, n (%)	37 (40.2%)	136 (40.6%)	
Ethnicity			0.02
Caucasian, n (%)	87 (94.6%)	331 (98.8%)	
African, n (%)	5 (5.4%)	4 (1.2%)	
BMI, median [IQR]	24.9 [23.0-28.5]	24.9 [23.0-27.5]	0.67
Abnormal waist circumference, n (%)	40 (43.5%)	128 (38.2%)	0.36
Obese patients, n (%)	10 (10.9%)	34 (10.1%)	0.84
Smoking status			0.172
Never, n (%)	80 (87.0%)	307 (91.6%)	
Past or current smokers, n (%)	12 (13.0%)	28 (8.4%)	
Alcohol intake			0.09
No, n (%)	87 (94.6%)	328 (97.9%)	
Yes, n (%)	5 (5.4%)	7 (2.1%)	
Diabetes, n (%)	13 (14.1)	65 (19.4)	0.25
Metabolic syndrome, n (%)	24 (26.1%)	83 (24.8%)	0.80
Arterial hypertension, n (%)	38 (41.3%)	137 (37.9%)	0.55
Cardiovascular diseases, n (%)	18 (19.6%)	58 (17.3%)	0.62
Kidney diseases, n (%)	6 (6.5%)	8 (2.4%)	0.05
Previous NHL, n (%)	9 (9.8%)	46 (13.7%)	0.31
Previous non-hematological neoplasia, n (%)	3 (3.3%)	7 (2.1%)	0.51
Use of NSBB at inclusion, n (%)	1 (1.1)	36 (10.8)	0.003
Sofosbuvir-based treatment, n (%)	64 (69.5)	279 (82.0)	0.09

1
2 *platelet count $>150.000/\text{mm}^3$ and $\text{TE}<20$ KPa
3 §platelet count $\leq 150.000/\text{mm}^3$ and/or $\text{TE}\geq 20$ KPa
4

5 TE, transient elastography; IQR, Inter Quartile Range; BMI, body mass index; NHL, Non-
6 Hodgkin's Lymphoma.; NSBB, non-selective beta blockers (propranolol or nadolol)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table 2. Baseline biochemical, virologic and liver-related characteristics of 427 patients included.

	Favorable Baveno VI status* N= 92 (21.5%) Group 1	Unfavorable Baveno VI status§ N= 335 (78.5%) Group 2	P
ALT (IU/mL), median [IQR]	67.0 [44.0-119.0]	70.0 [52.0-113.8]	0.46
GGT (IU/mL), median [IQR]	72.0 [35.5-125.0]	60.0 [48.0-98.8]	0.67
Albumin (g/dL), median [IQR]	4.3 [4.1-4.6]	4.1 [3.8-4.3]	0.0002
Total cholesterol (mg/dL), median [IQR]	149.0 [130.0-167.5]	130.0 [130.0-156.8]	0.001
HDL (mg/dL), median [IQR]	40.0 [31.5-50.0]	50.0 [40.0-50.0]	0.06
Triglycerides (mg/dL), median [IQR]	95.0 [76.5-114.5]	100.0 [80.0-106.8]	0.75
Platelets count (x10³/mm³), median [IQR]	192[164.0-225.0]	93.0 [61.0-117.0]	<0.0001
Platelets count (x10³/mm³), n (%)			
≤150	0 (0)	299 (89.3)	
>150	92 (100)	36 (10.7)	<0.0001
Liver stiffness (kPa), median [IQR]	14.4 [14.0-16.9]	21.3 [14.8-28.4]	<0.0001
Liver stiffness <20 kPa (n %)	92 (100)	147 (43.9)	<0.0001
Child-Turcotte-Pugh score			
A, n (%)	91 (98.9)	320 (95.5)	
B, n (%)	1 (1.1)	15 (4.5)	0.139
MELD score, median [IQR]	7.0 [6.0-7.0]	7.0 [7.0-9.0]	<0.0001
MELD <10, n (%)	88 (95.7)	286 (78.4)	
MELD 10-15, n (%)	3 (3.2)	71 (19.4)	0.006
MELD >15, n (%)	1 (1.1)	8 (2.2)	
Esophageal varices			
No, n (%)	88 (95.7)	232 (69.2)	
Grade 1, n (%)	3 (3.3)	67 (20.0)	<0.0001
Grade 2 or 3, n (%)	1 (1.0)	36 (10.8)	
Portal hypertensive gastropathy, n (%)	17 (17.9)	141 (42.1)	<0.0001

*platelet count >150.000/mm³ and TE<20 KPa

§platelet count ≤150.000/mm³ and/or TE≥20 KPa

1
2 TE, transient elastography; IQR, Inter Quartile Range; ALT, alanine aminotransferase; GGT,
3 gamma glutamyl transpeptidase; HDL, High-density lipoprotein; kPa, kilopascal; MELD,
4 Model of End Stage Liver Disease.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table 3. Association between baseline characteristics and development of EV in patients with unfavorable Baveno VI status and without EV at baseline.

Characteristics	Hazard ratio (95% CI)			
	Univariate	p	Multivariate	p
Age >65 years	1.01 (0.97-1.07)	0.46	1.07 (0.98-1.15)	0.12
Male gender	0.16 (0.02-1.12)	0.70	0.91 (0.25-3.38)	0.07
African ethnicity	0.22 (0.03-1.68)	0.15	0.23 (0.01-1.99)	0.19
Normal waist circumference	0.96 (0.89-1.03)	0.21	0.751 (0.55-1.02)	0.07
Obesity	1.94 (0.44-8.60)	0.39	1.89 (0.12-82.2)	0.51
BMI <25	0.65 (0.23-1.83)	0.41	0.74 (0.14-4.02)	0.72
Alcohol intake	N.F.*		N.F.*	
Metabolic syndrome	0.46 (0.10-2.03)	0.30	0.40 (0.09-2.76)	0.09
Diabetes	1.16 (0.33-4.11)	0.82	2.77 (0.88-35.87)	0.02
Arterial hypertension	1.49 (0.53-4.19)	0.45	10.46 (2.26-86,56)	0.08
Cardiovascular diseases	0.45 (0.06-3.39)	0.44	0.13 (0.006-3.06)	0.21
Kidney disease	N.F.*		N.F.*	
Neuropathy	N.F.*		N.F.*	
Previous NHL	2.24 (0.71-7.06)	0.17	2.09 (0.34-12.85)	0.43
Previous non-haematological neoplasia	3.31 (0.43-25.45)	0.25	75.59 (0.02-3161.93)	0.31
Liver stiffness > 25 kPa	1.004 (0.99-1.02)	0.55	1.01 (0.99-1.03)	0.40
MELD score <10	0.25 (0.08-0.73)	0.01	0.12 (0.02-0.88)	0.04
Child-Turcotte-Pugh score B	1.47 (0.19-11.35)	0.71	N.F.*	
ALT >ULN	1.003 (0.996-1.01)	0.35	1.01 (0.999-1.02)	0.06
AST >ULN	1.002 (0.992-1.01)	0.69	0.99 (0.97-1.004)	0.13
GGT >ULN	0.999 (0.99-1.004)	0.76	0.997 (0.99-1.006)	0.48
Platelet count >100000/mm ³	0.18 (0.06-0.58)	0.004	0.15 (0.02-0.94)	0.04
Albumin >4 g/dL	0.31 (0.11-0.87)	0.03	0.45 (0.06-3.19)	0.42

*N.F.: not feasible.

EV, esophageal varices; CI, confidence interval; BMI, body mass index; NHL, Non-Hodgkin lymphoma; MELD, model for end stage liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; ULN, upper limit of normal

Table 4. Association between baseline characteristics and EV worsening in patients with pre-therapy EV and unfavorable Baveno VI status.

Characteristics	Hazard ratio (95% CI)			
	Univariate	p	Multivariate	p
Age >65 years	1.03 (0.995-1.07)	0.09	1.06 (0.99-1.11)	0.05
Male gender	0.52 (0.24-1.13)	0.10	1.61 (0.17-1.37)	0.41
Normal waist circumference	1.002 (0.97-1.04)	0.93	1.001 (0.94-1.06)	0.98
Obesity	0.70 (0.32-1.51)	0.36	2.12 (0.56-.02)	0.27
BMI <25	0.78 (0.39-1.54)	0.47	0.61 (0.56-1.96)	0.41
Alcohol intake	N.F.*		N.F.*	
Metabolic syndrome	1.001 (0.40-2.47)	0.99	2.27 (0.28-18.66)	0.44
Diabetes	0.96 (0.39-2.36)	0.93	1.36 (0.25-7.43)	0.72
Arterial hypertension	1.02 (0.49-2.11)	0.97	0.79 (0.27-2.34)	0.67
Cardiovascular diseases	1.45 (0.59-3.58)	0.42	0.64 (0.18-2.24)	0.48
Kidney disease	N.F.*		N.F.*	
Neuropathy	N.F.*		N.F.*	
Previous NHL	1.53 (0.52--4.47)	0.44	2.96 (0.78-11.20)	0.11
Previous non-haematological neoplasia	N.F.*		N.F.*	
Liver stiffness > 25 kPa	1.03 (1.006-1.06)	0.01	1.04 (0.99-1.08)	0.05
MELD score <10	0.24 (0.11-0.50)	0.001	0.35 (0.12-1.03)	0.06
Child-Turcotte-Pugh score B	2.93 (0.97-8.84)	0.06	3.03 (0.48-19.23)	0.24
ALT >ULN	0.998 (0.99-1.005)	0.58	0.98 (0.96-1.005)	0.12
AST >ULN	1.002 (0.99-1.01)	0.63	1.03 (0.99-1.06)	0.05
GGT >ULN	0.99 (0.99-1.002)	0.13	0.99 (0.98 – 1.007)	0.41
Platelet count >100000/mm ³	0.35 (0.13 – 0.92)	0.03	0.36 (0.11-1.21)	0.10
Albumin >4 g/dL	0.48 (0.21-1.08)	0.08	0.35 (0.15-3.34)	0.20

*N.F.: not feasible.

EV, esophageal varices; CI, confidence interval; BMI, body mass index; NHL, Non-Hodgkin lymphoma; MELD, model for end stage liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; ULN, upper limit of normal

Table 5. Features associated with Baveno VI status improvement in patients with unfavorable Baveno VI status prior to therapy.

Features	Hazard ratio (95% CI)			
	Univariate	p	Multivariate	p
BMI <25	1.86 (1.28-2.71)	0.001	2.07 (1.41-3.03)	0.0002
MELD score <10	2.31 (1.13-4.74)	0.02	1.29 (0.58 – 2.84)	0.53
Pre-therapy EV	0.53 (0.35-0.81)	0.003	0.71 (0.46-1.11)	0.13
Platelet count >100000/mm³	3.55 (2.19-5.74)	<0.0001	3.64 (2.16-6.13)	<0.0001
Albumin >4 g/dL	1.34 (0.90-2.00)	0.15	0.70 (0.45-1.09)	0.13

CI, confidence interval; BMI, body mass index; MELD, model for end stage liver disease; EV, esophageal varices;

1
2
3 LEGENDS
4
5

6 Figure 1. Flow of the recruited patients
7


8 Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HIV, human
9 immunodeficiency virus; TE, transient elastography; OLT, orthotopic liver transplantation;
10
11
12
13 DAAs, direct-acting antiviral agents.
14
15
16
17

18 Figure 2. The Kaplan-Meier curves showing long-term EV incidence in patients with no
19 baseline EV according to their pre-therapy Baveno VI status.
20
21
22
23
24

25 Figure 3. Flow-chart suggesting need and timing of endoscopy for HCV-positive cirrhotic
26 patients achieving SVR after DAA treatment according to the dynamic of their Baveno VI
27 status.
28
29
30

31 Abbreviation: EV, esophageal varices; SVR, sustained virological response.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2





Figure 3






Figure 1. Flow of the recruited patients

Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HIV, human immunodeficiency virus; TE, transient elastography; OLT, orthotopic liver transplantation; DAAs, direct-acting antiviral agents.

190x274mm (169 x 169 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. The Kaplan-Meier curves showing long-term EV incidence in patients with no baseline EV according to their pre-therapy Baveno VI status.




Figure 3. Flow-chart suggesting need and timing of endoscopy for HCV-positive cirrhotic patients achieving SVR after DAA treatment according to the dynamic of their Baveno VI status. Abbreviation: EV, esophageal varices; SVR, sustained virological response.

274x190mm (117 x 117 DPI)